ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > PMN wishes from three weeks ago..

<< Previous

Bullboard Posts

Next >>

Comment by M101on Apr 16, 2021 1:45pm

160 Views

Post# 33012012

RE:RE:RE:RE:RE:RE:PMN wishes from three weeks ago..

Which is why the deal included the right participate in future financings on a prorated basis.
But it hardly matters as there are multiple corporate entities linked at arm's length. And while the rationale is to prevent an unfriendly takeover it has also been highy advantageous to the existing incompetent management who, again with their focus- (and spend) on-everything statement still appear to prefer delaying the one thing which will attract more institutional investors.

Does anyone seriously believe Goldstein and his enablers will go away quietly because at age 70 greed suddenly evaporates?

<< Previous

Bullboard Posts

Next >>

Investors eye Australian gold mining projects amid promising developments